Literature DB >> 35088164

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.

Laurent Poirel1,2,3, Mustafa Sadek1,4, Ayda Kusaksizoglu1, Patrice Nordmann5,6,7,8.   

Abstract

Cefiderocol (FDC) and ceftazidime-avibactam (CZA) are among the latest generation of commercialized antibiotics against carbapenem-resistant Gram negatives. However, emergence of CZA resistance is being increasingly reported, involving different KPC variants in Enterobacterales. By analyzing two CZA-resistant KPC-3 clinical variants, KPC-41 and KPC-50, we showed that KPC-41, and to a lesser extent KPC-50, may also have an impact on susceptibility to FDC leading to a cross-resistance. This feature highlights that a susceptibility testing to FDC is mandatory prior any clinical use of FDC for treating infections due to KPC producers.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cefiderocol; Ceftazidime-avibactam; Cross-resistance; KPC-41; KPC-50

Mesh：

Substances：

Year:  2022        PMID： 35088164     DOI： 10.1007/s10096-021-04397-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  19 in total

1.  Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Authors:  Krystyna M Kazmierczak; Douglas J Biedenbach; Meredith Hackel; Sharon Rabine; Boudewijn L M de Jonge; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Authors:  Vincenzo Di Pilato; Noemi Aiezza; Valentina Viaggi; Alberto Antonelli; Luigi Principe; Tommaso Giani; Francesco Luzzaro; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Authors:  David M Livermore; Marina Warner; Dorota Jamrozy; Shazad Mushtaq; Wright W Nichols; Nazim Mustafa; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

4.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.

Authors:  Peera Hemarajata; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

6.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 7.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 8.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

Review 9.  Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Authors:  Roopali Sharma; Tae Eun Park; Stanley Moy
Journal:  Clin Ther       Date:  2016-03-02       Impact factor: 3.393

10.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867
View more
  4 in total

Review 1.  New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.

Authors:  J Nicholas O'Donnell; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

Review 2.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

3.  Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.

Authors:  Laurent Poirel; Jose-Manuel Ortiz de la Rosa; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-03-22       Impact factor: 5.938

4.  Evolution of β-lactamase-mediated cefiderocol resistance.

Authors:  Christopher Fröhlich; Vidar Sørum; Nobuhiko Tokuriki; Pål Jarle Johnsen; Ørjan Samuelsen
Journal:  J Antimicrob Chemother       Date:  2022-08-25       Impact factor: 5.758
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.